Xgeva
FDA clears Amgen’s bone drug for multiple myeloma
January 8, 2018Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma
Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …
Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study
June 21, 2016Manufacturing and Production, Research and Development Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics
US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may …
Amgen files high earnings for Q1
April 22, 2015Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis
Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …
ABPI worried about Prolia use
March 10, 2014Sales and Marketing ABPI, Amgen, NHS, Xgeva
The ABPI has once again voiced concern that NHS patients in some areas of England are not getting access to …
Xgeva gains NICE recommendation for bone metastasis
August 17, 2012Sales and Marketing Amgen, NICE, Xgeva, bone metastatis
NICE is continuing to recommend Amgen’s Xgeva for certain groups of cancer patients whose disease has spread to their bones. …
NICE recommends Xgeva for bone metastasis
March 29, 2012Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer
NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …
Amgen bone cancer drug Xgeva approved in Europe
July 18, 2011Sales and Marketing Amgen, Prolia, Xgeva, denosumab
Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …
CHMP roundup
May 24, 2011Sales and Marketing CHMP, EMA, Fampyra, Vibativ, Victrelis, Xgeva, Yervoy
The latest products to be recommended for European approval include MSD’s Victrelis, Astellas Pharma Europe’s Vibativ, Amgen Europe’s Xgeva and …
Denosumab approved for bone cancer use
November 19, 2010Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab
Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …
